May 31, 2018 / 12:57 PM / 22 days ago

BRIEF-MEI Pharma And Helsinn Announce Positive Results In Myelodysplastic Syndrome Trial

May 31 (Reuters) - MEI Pharma Inc:

* MEI PHARMA AND HELSINN GROUP ANNOUNCE SUCCESSFUL INTERIM ANALYSIS OF PRACINOSTAT/AZACITIDINE PHASE 2 COMBINATION STUDY IN HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS

* MEI PHARMA INC - PREDEFINED PATIENT RETENTION THRESHOLD MET IN STUDY

* MEI PHARMA INC - 10% EARLY DISCONTINUATION RATE DUE TO ADVERSE EVENTS SUPPORTS EXPANSION OF PATIENT ENROLLMENT IN STUDY

* MEI PHARMA - BASED ON POSITIVE INTERIM ANALYSIS ANNOUNCED TODAY, HELSINN AND MEI ARE EXPANDING OPEN-LABEL ENROLLMENT TO TOTAL OF UP TO 60 MDS PATIENTS

* MEI PHARMA - 10% RATE CONSISTENT WITH ESTABLISHED DISCONTINUATION RATE FOR AZACITIDINE GIVEN AS MONOTHERAPY, MEETS THRESHOLD TO CONTINUE ENROLLMENT

* MEI PHARMA INC - STUDY DESIGN IS BEING AMENDED BY SUBSTITUTING STAGE 2 WITH AN EXPANDED OPEN-LABEL PORTION OF STUDY TO OBTAIN DATA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below